Gold prices bounce off 3-week lows; demand likely longer term
BOSTON - PureTech Health plc (Nasdaq:PRTC, LSE: PRTC), a clinical-stage biotherapeutics company, is set to present findings from its Phase 2b ELEVATE IPF trial at the American Thoracic Society International Conference in San Francisco on May 20, 2025. The trial evaluated deupirfenidone (LYT-100) for the treatment of idiopathic pulmonary fibrosis (IPF), a rare and fatal lung disease.
The ELEVATE IPF trial showed that deupirfenidone could potentially stabilize the decline in lung function over a 26-week period, while maintaining safety and tolerability. The trial included 257 participants, comparing two doses of deupirfenidone, a placebo, and the existing treatment pirfenidone. The primary measure was the rate of decline in Forced Vital Capacity (FVC), a key indicator of lung function.
Dr. Toby Maher, Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California, will deliver the presentation titled "Deupirfenidone Compared to Placebo and Pirfenidone in Idiopathic Pulmonary Fibrosis: ELEVATE IPF Phase 2b Trial."
PureTech plans to meet with the U.S. Food and Drug Administration by the end of the third quarter of 2025 to discuss the trial results and a potential Phase 3 trial. The company aims to initiate this next phase by the end of the year, with further details to be provided after finalizing the trial design and FDA interactions.
Deupirfenidone, a deuterated form of pirfenidone, one of the two FDA-approved treatments for IPF, seeks to offer better efficacy and tolerability than current treatments, which only modestly slow lung function decline. The drug may also address other underserved fibrotic diseases.
IPF affects over 230,000 people in the United States and the EU5, with a median survival of two to five years post-diagnosis. Current treatments have limited use, and a significant portion of patients in the United States have never received them.
This presentation is based on a press release statement from PureTech Health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.